

Oscar Prior Authorization Criteria

Summary of Changes – 11/2/26

Arikayce SGM 3150-A 2026a - Removed documentation requirements.

Sarclisa SGM 3643-A 2025a - Added the newly FDA-approved subcutaneous formulation, Sarclisa Escena (isatuximab-irfc), to the criteria.

Jaypirca SGM 5767-A 2025a - For CLL/SLL, removed requirement for previous trial of venetocax based regimen, per label update.

Nutritional Supplements-Tube Feeding Products PA (5 of 5) 340-A 01-2026 v2 - Added products to target drug list. Added products are highlighted.

Specialty Exceptions TKIs MF 7130-D 2026b – RETIRE POLICY - Added bosutinib as targeted product. No longer aligned with our formulary strategy so sunseting policy and using custom Non-Formulary Products Criteria (PG069).

Opdivo SGM 1894-A 2026b - Added coverage for use in combination with Tudriqev (vusolimogene oderparepvec-wtpg) for cutaneous melanoma, per Tudriqev package insert.

Revtorpyk SGM 7542-A 2026 - NEW - For treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer when used in combination with fulvestrant with or without palbociclib and does not have PIK3CA mutation, and has experienced progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Reauthorization if no unacceptable toxicity or disease progression.

Trutakna SGM 7545-A 2026 - NEW - Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy, proteinuria greater than or equal to 0.5 g/day or UPCR greater than or equal to 0.5 g/g, and received a stable dose of maximally tolerated renin-angiotensin system inhibitor therapy for at least 3 months prior to initiation of therapy.

Lytenava SGM 7579-A 2026 - NEW - Diagnosis of diabetic macular edema, neovascular (wet) aged-related macular degeneration, macular edema following retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization, neovascular glaucoma, and retinopathy of prematurity.

Jideytro SGM 7553-A 2026 - NEW - Diagnosis of locally advanced or metastatic ROS-1 positive non-small cell lung cancer as a single agent when the member has previously

received a ROS1 kinase inhibitor.